AOD-9604 vs Tirzepatide
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-20
An unproven GH fragment compared against the highest-efficacy weight-loss medication available
AOD-9604 failed its Phase III obesity trial and has no proven weight-loss effect in humans. Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist that produced 20-22% average body weight loss in the SURMOUNT-1 trial. This comparison lays out why the two are not really competing options.
This article is for informational purposes only and is not medical advice. Consult a physician before starting, stopping, or combining any peptide or prescription medication.
People researching AOD-9604 for weight loss often end up comparing it to tirzepatide — sold as Zepbound for weight management and Mounjaro for type 2 diabetes — because both get marketed in the same "peptide for fat loss" space. The comparison is lopsided: one is an FDA-approved drug with some of the strongest weight-loss trial data of any medication class, the other failed its own placebo-controlled trial.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →AOD-9604 vs Tirzepatide at a Glance
AOD-9604 and tirzepatide target weight loss through entirely different mechanisms, and only one has controlled human trial data to show for it.| Dimension | AOD-9604 | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | Isolated GH fragment (amino acids 176-191); proposed lipolytic activity | Dual GIP + GLP-1 receptor agonist; reduces appetite and slows gastric emptying |
| FDA status | Not approved; GRAS food-ingredient status only | FDA-approved for chronic weight management |
| Trial evidence | Phase III failed — no significant weight loss vs. placebo | SURMOUNT-1: ~20-22% average body weight loss at the highest dose |
| Dosing | Daily subcutaneous injection or oral troche (self-administered) | Weekly injection, 2.5-15 mg, titrated under physician supervision |
| Access | Unregulated research chemical | Prescription required |
| Monthly cost | $30-60 (research-grade) | ~$1,060/month list (Zepbound); often less with insurance or savings cards |
| Main side effects | None established in trials (trial failed on efficacy, not safety) | Nausea, diarrhea, vomiting, constipation (worst during dose escalation); boxed warning for a thyroid C-cell tumor signal seen in rodents |
Why the Weight-Loss Results Are Not Close
Tirzepatide's weight-loss effect is backed by a large randomized controlled trial program; AOD-9604's is not. In SURMOUNT-1, adults without diabetes lost an average of 20-22% of body weight on the highest tirzepatide dose over 72 weeks. AOD-9604's pivotal Phase III obesity trial, by contrast, showed no statistically significant weight loss versus placebo after 24 weeks of oral dosing — the program was discontinued for the obesity indication as a result.
This isn't a case of "more effective vs. less effective." It's a case of a drug with demonstrated efficacy versus a compound that did not beat placebo in the one controlled trial designed to test it.
Stacking AOD-9604 with Tirzepatide
Some users report combining AOD-9604 with tirzepatide, typically reasoning that AOD-9604 might add incremental fat-loss support on top of a GLP-1 medication. Because AOD-9604 has no demonstrated efficacy of its own, this combination has no trial evidence behind it — any effect attributed to AOD-9604 in that context cannot be separated from tirzepatide's own well-documented effect.
Anyone on prescription tirzepatide should discuss any additional compound, peptide, or supplement with their prescriber before adding it, particularly given tirzepatide's own side-effect profile and monitoring requirements.
Which Should You Consider?
Tirzepatide fits if: you want the weight-loss approach with the strongest trial evidence currently available, you can access it by prescription, and you can tolerate or manage the GI side effects during titration.
AOD-9604 fits if: the honest answer is that the trial evidence does not support choosing it for weight loss. See our full AOD-9604 review for the complete trial history, and tirzepatide vs semaglutide if you're comparing GLP-1 options against each other instead.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is AOD-9604 as effective as tirzepatide for weight loss?
No. Tirzepatide (Zepbound) produced 20-22% average body weight loss in the SURMOUNT-1 trial. AOD-9604's own Phase III obesity trial found no statistically significant weight loss versus placebo. The two are not comparable in demonstrated efficacy.
Can you take AOD-9604 with tirzepatide?
Some people self-stack the two, but no controlled trial has tested this combination, and AOD-9604 has no demonstrated weight-loss effect of its own to add. Anyone on prescription tirzepatide should discuss any additional compound with their prescriber first, especially given tirzepatide's side-effect and monitoring requirements.
Why is tirzepatide so much more expensive than AOD-9604?
Tirzepatide is a patented, FDA-approved prescription drug that went through full clinical development and regulatory review, reflected in Zepbound's roughly $1,060/month list price (often less with insurance or manufacturer savings programs). AOD-9604 is an unregulated research chemical with no development or regulatory costs behind its $30-60/month price — and no proven effect to show for it either.
Does AOD-9604 work like a GLP-1 drug?
No. AOD-9604 is a fragment of growth hormone with a proposed lipolytic (fat-burning) mechanism. Tirzepatide is a dual GIP/GLP-1 receptor agonist that reduces appetite and slows gastric emptying. The two work through completely different biological pathways, and only tirzepatide has controlled trial data confirming its effect in humans.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
AOD-9604 vs HGH Fragment 176-191: Are They the Same Peptide?
AOD-9604 vs HGH Fragment 176-191: naming confusion, history, and what the evidence shows.
-
AOD-9604 vs Tesamorelin: Which Fat-loss Peptide Has Real Evidence?
AOD-9604 vs tesamorelin: failed obesity trial vs FDA-approved visceral-fat peptide.
-
AOD-9604 vs MOTS-c: Comparing Two Unproven Research Peptides
AOD-9604 vs MOTS-c: comparing two unproven research peptides with different target claims.
See more related comparisons
-
AOD-9604: the Fat-loss Peptide That Failed Phase III — and What Works Instead
AOD-9604: the GH fragment that failed Phase III, why it's still sold, and what actually works for fat loss.
-
Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Compared
Retatrutide vs tirzepatide: investigational triple agonist vs FDA-approved dual agonist.
-
Semaglutide vs Tirzepatide vs Retatrutide: Single, Dual, and Triple Hormone Agonists Compared
Semaglutide vs tirzepatide vs retatrutide: single, dual, and triple hormone agonists compared side by side.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.